Carotid intima-media thickness: a target or a marker?
Tiziana Montalcini1, Stefano Romeo, Antonietta Fava
11Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy; and 2Department of Molecular and Clinical Medicine, Sahlgrenska Center for Cardiovascolar and Metabolic Research, University of Gothenburg, Gothenburg, Sweden.
American Journal of Therapeutics
|September 27, 2012
Summary
Choosing appropriate clinical trial endpoints is crucial for evidence-based medicine. While carotid intima-media thickness is a surrogate, low-density lipoprotein cholesterol better predicts cardiovascular outcomes and treatment effectiveness.
Area of Science:
- Cardiovascular Medicine
- Clinical Trial Design
- Pharmacological Research
Background:
- Evidence-based medicine necessitates validated pharmacological agents for disease reduction.
- Selecting appropriate efficacy endpoints in clinical trials is a significant challenge.
- Surrogate endpoints can reduce trial costs but risk misleading conclusions.
Purpose of the Study:
- To evaluate the suitability of carotid intima-media thickness as a surrogate endpoint in cardiovascular pharmacological studies.
- To compare the predictive value of carotid intima-media thickness and low-density lipoprotein cholesterol for cardiovascular events.
- To assess the impact of interventions targeting carotid intima-media thickness on clinical outcomes.
Main Methods:
- Review of existing pharmacological studies utilizing carotid intima-media thickness as a surrogate endpoint.
- Analysis of data correlating carotid intima-media thickness changes with cardiovascular event rates.
- Comparison of intervention effects on carotid intima-media thickness versus established cardiovascular biomarkers and clinical outcomes.
Main Results:
- Interventions targeting carotid intima-media thickness often fail to demonstrate significant impact on final clinical endpoints.
- Carotid intima-media thickness may not accurately reflect the true efficacy of cardiovascular prevention strategies.
- Low-density lipoprotein cholesterol levels serve as a reliable biomarker for predicting cardiovascular outcomes.
Conclusions:
- Carotid intima-media thickness may be an unreliable surrogate endpoint for cardiovascular prevention trials.
- Low-density lipoprotein cholesterol is a superior biomarker for assessing the efficacy of cardiovascular interventions.
- Relying solely on carotid intima-media thickness could lead to the marketing of drugs with questionable cardiovascular benefits.
Related Concept Videos
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
01:26Aneurysm III: Interprofessional Care
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...